The Positive Effect of HT on the Treatment of Menopausal Symptoms

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 411

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

LAMOGMED03_083

تاریخ نمایه سازی: 21 بهمن 1397

Abstract:

Introduction: Hormone therapy is widely used to control the menopause symptoms. This study was performed with the aim of Conditions of use hormone therapy.Material & Methods: The aim of this review is about the issue of recurrent menopausal symptoms and hormone therapy. This study was performed of a systematic literature using the keywords menopause, hormone therapy. and electronic databases PubMed, Cochrane, Embase, ProQuest and Science direct from 2010 to present.Results: Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, and duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT.For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture. For women who initiate HT more than 10 or 20 years from menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. For bothersome GSM symptoms not relieved with over-the-counter therapies and without indications for use of systemic HT, low-dose vaginal estrogen therapy or other therapies are recommended.Conclusion: According to the results, during the administration of the HT, all conditions in the patient should be evaluated.

Keywords:

menopause , hormone therapy.Reference: Electronic databases: PubMed , Google Scholar , ProQuest , IranMedex and Science direct from 2010 to present

Authors

Somayeh Fallah

MSc of Midwifery Faculty Member of Nursing and Midwifery school, Qazvin University of Medical Science, Qazvin, Iran

Masoumeh Dadashaliha

Gynecologist & obstetrics, Faculty Member of Medicine School, Qazvin University of Medical Science, Qazvin, Iran

Zahra Bajalan

MSc of Midwifery Faculty Member of Nursing and Midwifery school, Qazvin University of Medical Science, Qazvin, Iran